Article

  • The EMBO Journal (2002) 21, 665 - 674
  • doi:10.1093/emboj/21.4.665

Oncogenic potential of a C.elegans cdc25 gene is demonstrated by a gain-of-function allele

Caroline Clucas1, Juan Cabello2, Ingo Büssing2, Ralf Schnabel2 and Iain L. Johnstone1

  1. The Wellcome Centre for Molecular Parasitology, The University of Glasgow, Anderson College, 56 Dumbarton Road, Glasgow, UK
  2. Institut für Genetik, TU Carolo Wilhelmina, Spielmann Strasse 7, D-38106 Braunschweig, Germany

Correspondence to:

Iain L. Johnstone, E-mail: i.johnstone@vet.gla.ac.uk

Received 8 November 2001; Accepted 12 December 2001; Revised 12 December 2001


In multicellular organisms, developmental programmes must integrate with central cell cycle regulation to co-ordinate developmental decisions with cell proliferation. Hyperplasia caused by deregulated proliferation without significant change to other aspects of developmental behaviour is a probable step towards full oncogenesis in many malignancies. CDC25 phosphatase promotes progression through the eukaryotic cell cycle by dephosphorylation of cyclin-dependent kinase and, in humans, different cdc25 family members have been implicated as potential oncogenes. Demonstrating the direct oncogenic potential of a cdc25 gene, we identify a gain-of-function mutant allele of the Caenorhabditis elegans gene cdc-25.1 that causes a deregulated proliferation of intestinal cells resulting in hyperplasia, while other aspects of intestinal cell function are retained. Using RNA-mediated interference, we demonstrate modulation of the oncogenic behaviour of this mutant, and show that a reduction of the wild-type cdc-25.1 activity can cause a failure of proliferation of intestinal and other cell types. That gain and loss of CDC-25.1 activity has opposite effects on cellular proliferation indicates its critical role in controlling C.elegans cell number.

  • Keywords:

    • cdc25,
    • cell cycle,
    • C.elegans,
    • development,
    • oncogene